Ropeginterferon Alfa-2B Dosage
Medically reviewed by Drugs.com. Last updated on Jun 27, 2023.
Applies to the following strengths: 500 mcg/mL
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Polycythemia Vera
For Patients NOT Receiving Hydroxyurea:
Initial dose: 100 mcg subcutaneously every 2 weeks
- Increase the dose in increments of 50 mcg every 2 weeks until the hematologic parameters stabilize
For Patients TRANSITIONING from Hydroxyurea:
Initial dose: 50 mcg subcutaneously every 2 weeks in combination with hydroxyurea
- Gradually taper off hydroxyurea in weeks 3 through 12 by reducing total biweekly dose by 20% to 40% every 2 weeks while increasing this drug in increments of 50 mcg every 2 weeks until the hematologic parameters stabilize; discontinue hydroxyurea by week 13
Stabilized Hematologic Parameters:
- Hematocrit less than 45%
- Platelets less than 400 x 10(9)/L
- Leukocytes less than 10 x 10(9)/L
Maintenance dose:
- Maintain 2-week dosing interval with hematological stability for at least 1 year
- After 1 year of hematological stability on a stable dose, the dosing interval may be expanded to every 4 weeks
Comments:
- Patients should be monitored closely; complete blood counts (CBC) should be obtained every 2 weeks during titration and every 3 to 6 months during maintenance phase, and as clinically indicated.
- Phlebotomy may be necessary as rescue treatment to normalize blood hyperviscosity,
Use: For the treatment of polycythemia vera.
Renal Dose Adjustments
eGFR 30 mL/min: No adjustment recommended
eGFR less than 30 mL/min: Avoid use
Discontinue therapy if severe renal impairment develops during treatment
Liver Dose Adjustments
Mild hepatic impairment: No adjustment recommended
Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment: Use is contraindicated
See Dose Adjustments for dose modifications due to elevated hepatic transaminases
Dose Adjustments
DOSE MODIFICATIONS FOR ADVERSE REACTIONS:
- If there is insufficient efficacy at the decreased dose following dose modification, consider increasing dose to the next higher dose level after recovery to grade 1 toxicity
HEPATIC:
- Liver enzyme elevations ABOVE BASELINE with concomitant bilirubin elevation or other evidence of hepatic decompensation: Interrupt until recovery; restart at 50 mcg lower than interrupted dose. If interrupted dose is 50 mcg, hold until recovery; consider permanent discontinuation if toxicity persists after 4-dose modifications
- Liver enzyme elevations GREATER THAN 5 to 20 x ULN (upper limit of normal): Decrease dose by 50 mcg and if toxicity does not improve, continue decreasing at biweekly intervals until transaminases (ALT and AST) recover to less than 3 x ULN if baseline was normal (or 3 x baseline if baseline was abnormal), and gamma-glutamyltransferase (GGT) recovers to less than 2.5 x ULN if baseline was normal (or 2.5 x baseline if baseline was abnormal). If the interrupted dose is 50 mcg, refrain from treatment until recovery
- Liver enzyme elevations GREATER THAN 20 x ULN: Interrupt treatment until ALT and AST recover to less than 3 x ULN if baseline was normal (or 1.5 x baseline if baseline was abnormal), and GGT recovers to less than 2.5 x ULN if baseline was normal (or 2 x baseline if baseline was abnormal). Consider permanent discontinuation if toxicity persists after 4 dose-modifications.
HEMATOLOGIC:
- ANEMIA: For Hb less than 8 g/dL: Decrease dose by 50 mcg, if toxicity does not improve, continue decreasing at bi-weekly intervals until recovery to 10 g/dL; Interrupt therapy if Hb levels are life threatening, or urgent intervention is needed until recovery to greater than 10 g/dL
- THROMBOCYTOPENIA: For platelet count less than 50,000/mm3 but at 25,000/mm3 or greater: Decrease dose by 50 mcg, if toxicity does not improve, continue decreasing at bi-weekly intervals until recovery to greater than 75,000 mm3; interrupt therapy if platelet count is less than 25,000/mm3 until recovery to 75,000/mm3
- LEUKOPENIA: For WBCs less than 2000/mm3 but at 1000/mm3 or greater: Decrease dose by 50 mcg, if toxicity does not improve, continue decreasing at biweekly intervals until recovery to greater than 3000/mm3; interrupt therapy if WBC is less than 1000/mm3 until recovery to 3000/mm3
DEPRESSION:
- MILD, without suicidal ideation: Consider psychiatric consultation if persists greater than 8 weeks
- MODERATE, without suicidal ideation: Consider dose reduction and psychiatric consultation
- SEVERE, or any severity with suicidal ideation: Discontinue therapy, recommend psychiatric consultation
Precautions
US BOXED WARNING: RISK OF SERIOUS DISORDERS
- Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders.
- Patients should be monitored closely with periodic clinical and laboratory evaluations.
- Therapy should be withdrawn for persistently severe or worsening signs or symptoms of these conditions; most cases resolved after stopping therapy.
CONTRAINDICATIONS:
- Hypersensitivity to interferons including interferon alfa-2b or any product ingredients
- Existence of, or history of severe psychiatric disorders, particularly severe depression, suicidal ideation, or suicide attempt
- Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment
- History or presence of active serious or untreated autoimmune disease
- Immunosuppressed transplant recipients
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- For subcutaneous administration into lower stomach (abdomen) or top of thighs
- Rotate injection sites; do not inject into skin that is irritated, red, bruised, infected, or scarred
- Self-administration should be reserved for patients who have received training on storage, preparation, and administration
Storage requirements:
- Store refrigerated 36F to 46F (2C to 8C) in the original carton to protect from light; do not freeze
Reconstitution/preparation techniques:
- Patients should be instructed to follow the enclosed Instructions for Use
Monitoring:
- CBC at baseline and every 2 weeks during titration, then at least every 3 to 6 months, and as clinically indicated
- Monitor serum triglycerides at baseline and intermittently during therapy
- Monitor liver function tests at baseline and during therapy; if AST/ALT/GGT elevations occur, monitor weekly until resolution
- Monitor serum creatinine at baseline and during therapy
- Monitor for neuropsychiatric, autoimmune, ischemic, and infections disorders
Patient advice:
- Patients should be instructed to read the US FDA-approved patient labeling (Medication Guide and Instructions for Use).
- Patients/caregivers should be advised to promptly report any unusual changes in mood or behavior, new onset or worsening of depression, or the emergence of suicidal thoughts or behavior.
- Patients/caregivers should be advised to report any symptoms of diabetes, thyroid dysfunction, cardiovascular toxicity, fatigue, fever, easy bruising, or frequent nose bleeds.
- Patients should be advised to maintain good oral hygiene and to have regular dental examinations.
- Patients should be advised to refrain from engaging in operating heavy or potentially dangerous machinery until they know how this drug will affect them; if they experience dizziness, somnolence, or hallucinations, they should not drive or use heavy machinery.
- Women should be advised to use an effective method of contraception and avoid breastfeeding while taking this drug and for at least 8 weeks after their last dose.
More about ropeginterferon alfa-2b
- Check interactions
- Compare alternatives
- Reviews (1)
- Side effects
- During pregnancy
- Drug class: antineoplastic interferons
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.